Health :: Antibiotic Ceftobiprole shows promise against MRSA infections

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. today announced that ceftobiprole, a novel cephalosporin(1) antibiotic in Phase III clinical trials, was found to be active against complicated skin infections caused by common, potentially deadly bacteria, including MRSA. These data were from two poster presentations given at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). These data also were highlighted by ICAAC. Ceftobiprole is being co-developed with Basilea Pharmaceutica, Ltd. through an exclusive worldwide collaboration.

Fertility :: Sperm donors could transmit genetic disorders to children

Even as fertility procedures such as in-vitro fertilization and donor insemination become more commonplace day-by-day, a new study has researchers warning people that even after thorough screenings of sperm donors, genetic disorders can be transmitted to the child conceived through such procedures.

Diet :: Guidance for the Safe Production of Fresh-Cut Fruits and Vegetables

To minimize microbial food safety hazards common to the processing of most fresh-cut fruits and vegetables sold to consumers in a ready-to-eat form, The Food and Drug Administration (FDA) published a draft guidance document for producers of fresh-cut produce entitled “Guide to Minimize Microbial Food Safety Hazards of Fresh-cut Fruits and Vegetables.”

Deafness :: Cochlear Implant Risks

Children with an early version of the cochlear implant face an increased risk of bacterial meningitis beyond just the first two years following implantation of the hearing devices, the Food and Drug Administration warned.

Impetigo :: What is impetigo

Impetigo is a skin disorder caused by bacterial infection and characterized by crusting skin lesions. It is a superficial skin infection most common among children age 2-6 years (rare among people not in this age group).

Tuberculosis :: How Promising TB Drug Works

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined how a promising drug candidate attacks the bacterium that causes tuberculosis (TB). Published online this week in Proceedings of the National Academy of Sciences, the finding may help scientists optimize the drug candidate, PA-824, which targets Mycobacterium tuberculosis (M. tb).

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack